Feature | SCAI | May 08, 2019

Late-breaking Interventional Cardiology Presentations at SCAI 2019

Here is the list of featured clinical research at the Society for Cardiovascular Angiography and Interventions annual meeting

Khaldoon Alaswad, M.D., FSCAI, right, during a chronic total occlusion (CTO) case in his lab at Henry Ford Hospital, Detroit. He is presenting in several SCAI 2019 sessions.  SCAI 2019 late breaking sessions, SCAI featured research sessions.

Khaldoon Alaswad, M.D., FSCAI, right, during a chronic total occlusion (CTO) case in his lab at Henry Ford Hospital, Detroit. He is presenting in several SCAI 2019 sessions.  

May 8, 2019 — The Society for Cardiovascular Angiography and Interventions (SCAI) 2019 Scientific Sessions will take place May 19-22, 2019 at the Cosmopolitan of Las Vegas in Las Vegas, Nev. The biggest news will be from the featured clinical research sessions that highlight the latest advances in interventional cardiology. Here is at the list of sessions:

 

Featured Clinical Research, Part I 
   • A Risk Score to Predict Post-Discharge Bleeding Among Acute Coronary Syndrome Patients Undergoing Percutaneous Coronary Intervention: BRIC-ACS Study, presented by Yundai Chen.

   • AVIATOR-2: Antithrombotic Strategy Variability in Atrial Fibrillation and Obstructive Coronary Disease Revascularized with Percutaneous Coronary Intervention Registry, presented by Ridhima Goel, M.B.B.S

   • Plaque Regression and Endothelial Progenitor Cell Mobilization With Intensive Lipid Elimination Regimen (PREMIER), presented by Subhash Banerjee, M.D., FSCAI.

   • Superior Vena Caval Occlusion in Acute Decompensated Heart Failure: First-in-Human Experience, presented by Navin K. Kapur, M.D., FSCAI.

   • Improved Outcomes May Be Associated With the Use of Shock Protocols: Updates From the National Cardiogenic Shock Initiative, presented by Mir Basir, D.O.

 

Featured Clinical Research, Part II
   • A Global Registry of Fractional Flow Reserve (FFR)-Guided Management During Routine Clinical Procedures, presented by Erick Schampaert, M.D.

   • Derivation and Validation of Pd/Pa for the Assessment of Residual Ischemia Post Intervention - A Prospective All Comer Registry, presented by Abdul Hakeem, M.D., FSCAI.

   • First-in-Human Study of the Saranas Early Bird Bleed Monitoring System for the Detection of Endovascular Procedure Related Bleeding Events, presented by Philippe Genereux, M.D.

   • Impact of Intravascular Ultrasound-Guided Drug-Eluting Stent Implantation on Patients With Chronic Kidney Disease: Results From ULTIMATE Trial, presented by Junjie Zhang, M.D., FSCAI.

   • Vascular Closure Device Type Impacts Bleeding and Vascular Complications After TAVR: Results From the BRAVO 3 Randomized Trial, presented by David A. Power, MB BCh. 

 

Other SCAI 2019 News:

Cardiac Cath Lab Economics Consensus Statement Released by SCAI and ACVP

SCAI Releases New Consensus Document on Classification Stages of Cardiogenic Shock

Philips Launches IntraSight Interventional Applications Platform

Impella SmartAssist Platform Launches at SCAI

Cordis Announces U.S. Launch of Radial 360 Portfolio

For more information on these or other sessions, visit: www.scai.org/SCAI2019

 

Other Recent Late-breaking Cardiology Trials:

SCAI 2018 Late-breaking Clinical Trials

ACC 2019 Late-breaking Presentations

TCT 2018 Late-breaking Cardiovascular Clinical Trials

EuroPCR 2018 Late-breaking Trials in Interventional Cardiology

Heart Rhythm 2018 Late-breaking Studies

 

 

#SCAI2019  #SCAI19  #SCAI

Related Content

FDA Issues Final Guidance on Live Case Presentations During IDE Clinical Trials
News | Cardiovascular Clinical Studies | July 10, 2019
The U.S. Food and Drug Administration (FDA) issued the final guidance “Live Case Presentations During Investigational...
Veradigm Partners With American College of Cardiology on Next-generation Research Registries
News | Cardiovascular Clinical Studies | July 03, 2019
The American College of Cardiology (ACC) has partnered with Veradigm, an Allscripts business unit, to power the next...
New FDA Proposed Rule Alters Informed Consent for Clinical Studies
News | Cardiovascular Clinical Studies | November 19, 2018
The U.S. Food and Drug Administration (FDA) is proposing to add an exception to informed consent requirements for...
A key slide from Elnabawi's presentation, showing cardiac CT plaque evaluations, showing the impact of psoriasis medication on coronary plaques at baseline and one year of treatment. It shows a reversal of vulnerable plaque development. #SCAI, #SCAI2018

A key slide from Elnabawi's presentation, showing cardiac CT plaque evaluations, showing the impact of psoriasis medication on coronary plaques at baseline and one year of treatment. It shows a reversal of vulnerable plaque development.  

Feature | Cardiovascular Clinical Studies | May 14, 2018
May 14, 2018 – New clinical evidance shows common therapy options for psoriasis (PSO), a chronic inflammatory skin di
Intravenous Drug Use is Causing Rise in Heart Valve Infections, Healthcare Costs. #SCAI, #SCAI2018
News | Cardiovascular Clinical Studies | May 14, 2018
May 14, 2018 — The opioid drug epidemic is impacting cardiology, with a new study finding the number of patients hosp
Patient Enrollment Completed in U.S. IDE Study of THERMOCOOL SMARTTOUCH SF Catheter
News | Cardiovascular Clinical Studies | March 15, 2018
March 15, 2018 –  Johnson & Johnson Medical Devices Companies announced today that Biosense Webster, Inc., who wo
Lexington Begins HeartSentry Clinical Trial
News | Cardiovascular Clinical Studies | February 20, 2018
February 20, 2018 – Lexington Biosciences, Inc., a development-stage medical device company, announced the commenceme
Endologix Completes Patient Enrollment in the ELEVATE IDE Clinical Study
News | Cardiovascular Clinical Studies | February 06, 2018
February 6, 2018 – Endologix, a developer and marketer of treatments for aortic disorders, announced the completion o
12-Month Results from Veryan Medical's MIMICS-2 IDE Study Presented at LINC
News | Cardiovascular Clinical Studies | February 01, 2018
February 1, 2018 – Thomas Zeller (Bad Krozingen, Germany) presented the 12-month results from Veryan Medical’s MIMICS
LimFlow Completes U.S. Feasibility Study Enrollment, Receives FDA Device Status
News | Cardiovascular Clinical Studies | February 01, 2018
February 1, 2018 –  LimFlow SA, developer of minimally-inv
Overlay Init